Journal: NPJ Vaccines
Article Title: pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy model
doi: 10.1038/s41541-025-01147-4
Figure Lengend Snippet: a Western blot of soluble hippocampal lysates from Qβ Control and Qβ-PHF1 vaccinated rTg4510 mice were evaluated for markers of phosphorylated (AT8, AT180, PHF1) and total tau (Tau5). All samples were run on the same gel. b Compared to Qβ Control vaccinated mice, Qβ-PHF1 vaccinated mice showed a significant reduction in pathological AT180 + tau without any reduction in total physiologic tau. c . Immunohistochemistry of brain sections from Qβ Control and Qβ-PHF1 vaccinated rTg4510 mice staining for AT180 tau pathology in the cerebral cortex (CTX) and CA1 hippocampus. d There was a significant reduction in AT180 + tau pathology in both the cortex and hippocampus of Qβ-PHF1 vaccinated mice compared to Qβ Control mice ( e , f ). Western blot of soluble hippocampal lysates from Qβ Control and Qβ-AT8 vaccinated rTg4510 mice showed no significant reductions in pathological tau. All graphs display mean ± SEM. Student’s t -test ( b , d , f ). p < 0.05*; p < 0.001***; p < 0.0001****. Qβ Control ( n = 5), Qβ-AT8 ( n = 7), Qβ-PHF1 ( n = 8).
Article Snippet: Antibody dilutions were as follows: AT180 (Thermo Fisher Scientific, MN1040) at 1:500, AT8 (Thermo Fisher Scientific, MN1020) at 1:500, Iba1 (WAKO, 019-19741) at 1:500, and CD45 (BioRad, MCA43R) at 1:250 incubated overnight at 4 °C.
Techniques: Western Blot, Control, Immunohistochemistry, Staining